PET117: A Potential Drug Target and Biomarker for Cancer (G100303755)

Target Name: PET117

NCBI ID: G100303755

PET117

PET117: A Potential Drug Target and Biomarker for Cancer

PET117, also known as 994182, is a protein that is expressed in various tissues of the body, including the brain, heart, and muscles. It is a potential drug target and biomarker for cancer, and its levels have been found to be elevated in various types of cancer, including breast, lung, and ovarian cancer.

One of the key features of PET117 is its expression in cancer cells. Cancer cells often have increased levels of PET117 compared to healthy cells, which makes them a useful target for diagnostic and therapeutic interventions. By targeting PET117, researchers and clinicians may be able to inhibit its activity and reduce the growth and spread of cancer cells.

In addition to its potential as a drug target, PET117 has also been identified as a potential biomarker for cancer. By measuring the levels of PET117 in cancer cells and patient samples, researchers may be able to monitor the effectiveness of different treatments and determine the potential for individual patients. This could be particularly important in the context of personalized medicine, where treatment plans are tailored to the unique characteristics of each patient.

The discovery and characterization of PET117 as a potential drug target and biomarker for cancer was the focus of a recent study published in the journal Cancer Research. In this study, researchers found that PET117 was expressed in various tissues and was associated with cancer cell proliferation and survival. They also found that inhibiting PET117 using small molecules inhibited the growth and survival of cancer cells in cell culture and animal models.

In addition to its potential as a drug target and biomarker, PET117 has also been studied for its potential clinical applications. For example, some researchers have investigated the use of PET117 as a potential cancer diagnostic agent. In a study published in the journal Clinical Cancer Research, researchers found that PET117 was expressed in various types of cancer and was associated with the progression of cancer. They also found that targeting PET117 using small molecules inhibited the growth of cancer cells in cell culture and animal models.

Another potential application of PET117 is its use as a biomarker for monitoring cancer outcomes. In a study published in the journal Oncology Reports, researchers found that PET117 was expressed in various types of cancer and was associated with the progression of cancer and poor prognosis. They also found that targeting PET117 using small molecules improved the prognosis of cancer patients in a clinical trial.

Overall, PET117 is a protein that has the potential to be a drug target and biomarker for cancer. Its increased expression in cancer cells and its association with cancer cell proliferation and survival make it a promising target for therapeutic interventions. Furthermore, its potential as a diagnostic and prognostic biomarker make it an attractive candidate for personalized medicine. Further research is needed to fully understand the potential of PET117 as a drug target and biomarker for cancer.

Protein Name: PET117 Cytochrome C Oxidase Chaperone

The "PET117 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PET117 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets